 Charles Hoeffer
Concepts (314)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Long-Term Potentiation | 10 | 2017 | 198 | 1.890 |
Why?
| | Proto-Oncogene Proteins c-akt | 4 | 2025 | 437 | 1.880 |
Why?
| | Muscle Proteins | 4 | 2022 | 231 | 1.820 |
Why?
| | Intracellular Signaling Peptides and Proteins | 5 | 2015 | 455 | 1.510 |
Why?
| | Neuronal Plasticity | 12 | 2017 | 290 | 1.280 |
Why?
| | Protein Biosynthesis | 5 | 2021 | 433 | 1.190 |
Why?
| | Astrocytes | 3 | 2025 | 210 | 1.130 |
Why?
| | Down Syndrome | 4 | 2022 | 496 | 1.080 |
Why?
| | Hippocampus | 11 | 2017 | 895 | 1.040 |
Why?
| | Memory | 6 | 2021 | 248 | 1.030 |
Why?
| | Behavior, Animal | 9 | 2023 | 501 | 1.000 |
Why?
| | Nicotinic Agonists | 2 | 2025 | 129 | 0.970 |
Why?
| | Nicotine | 2 | 2025 | 334 | 0.890 |
Why?
| | Alzheimer Disease | 4 | 2022 | 560 | 0.890 |
Why?
| | Neurons | 10 | 2024 | 1590 | 0.880 |
Why?
| | Calcium-Binding Proteins | 3 | 2022 | 218 | 0.870 |
Why?
| | Epistasis, Genetic | 2 | 2023 | 70 | 0.810 |
Why?
| | Brain | 4 | 2020 | 2668 | 0.800 |
Why?
| | Tauopathies | 3 | 2025 | 13 | 0.770 |
Why?
| | Chronobiology Disorders | 1 | 2022 | 13 | 0.770 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 2023 | 89 | 0.760 |
Why?
| | DNA-Binding Proteins | 5 | 2023 | 1502 | 0.720 |
Why?
| | Mice, Knockout | 17 | 2025 | 3015 | 0.700 |
Why?
| | Spatial Memory | 1 | 2020 | 26 | 0.690 |
Why?
| | Mice | 34 | 2025 | 17787 | 0.680 |
Why?
| | Dendritic Spines | 2 | 2021 | 65 | 0.670 |
Why?
| | Extinction, Psychological | 1 | 2020 | 86 | 0.640 |
Why?
| | Animals | 43 | 2025 | 36940 | 0.630 |
Why?
| | Interleukin-17 | 2 | 2017 | 119 | 0.630 |
Why?
| | Synapses | 9 | 2017 | 427 | 0.620 |
Why?
| | Signal Transduction | 11 | 2016 | 5079 | 0.600 |
Why?
| | Aging | 2 | 2022 | 1864 | 0.600 |
Why?
| | TOR Serine-Threonine Kinases | 6 | 2014 | 412 | 0.590 |
Why?
| | tau Proteins | 4 | 2025 | 90 | 0.560 |
Why?
| | Basolateral Nuclear Complex | 1 | 2017 | 11 | 0.530 |
Why?
| | Eukaryotic Initiation Factor-4E | 2 | 2021 | 27 | 0.530 |
Why?
| | Memory, Long-Term | 2 | 2020 | 12 | 0.530 |
Why?
| | Memory Consolidation | 1 | 2017 | 12 | 0.530 |
Why?
| | Mice, Inbred C57BL | 13 | 2025 | 5757 | 0.530 |
Why?
| | Anxiety | 5 | 2023 | 1035 | 0.530 |
Why?
| | Transcriptome | 1 | 2023 | 971 | 0.520 |
Why?
| | Fragile X Syndrome | 3 | 2012 | 77 | 0.510 |
Why?
| | Sleep | 2 | 2024 | 755 | 0.500 |
Why?
| | Nerve Degeneration | 1 | 2015 | 46 | 0.490 |
Why?
| | Genome-Wide Association Study | 4 | 2023 | 1431 | 0.470 |
Why?
| | Autism Spectrum Disorder | 2 | 2017 | 395 | 0.450 |
Why?
| | Up-Regulation | 2 | 2021 | 843 | 0.440 |
Why?
| | Protein Synthesis Inhibitors | 2 | 2012 | 47 | 0.440 |
Why?
| | Gene Expression Regulation | 6 | 2017 | 2607 | 0.440 |
Why?
| | Mice, Transgenic | 9 | 2025 | 2167 | 0.430 |
Why?
| | Sensory Gating | 2 | 2013 | 45 | 0.420 |
Why?
| | Fluoxetine | 1 | 2013 | 54 | 0.410 |
Why?
| | Disease Models, Animal | 12 | 2025 | 4295 | 0.410 |
Why?
| | GABAergic Neurons | 1 | 2013 | 35 | 0.400 |
Why?
| | Eukaryotic Initiation Factor-4F | 1 | 2012 | 3 | 0.400 |
Why?
| | Gene Expression | 1 | 2017 | 1502 | 0.390 |
Why?
| | Protein Phosphatase 1 | 2 | 2013 | 33 | 0.380 |
Why?
| | Interneurons | 1 | 2013 | 122 | 0.380 |
Why?
| | Mental Disorders | 1 | 2020 | 1077 | 0.370 |
Why?
| | Receptors, Nicotinic | 3 | 2025 | 334 | 0.360 |
Why?
| | Mitochondria | 2 | 2015 | 948 | 0.360 |
Why?
| | Eukaryotic Initiation Factor-4G | 1 | 2011 | 5 | 0.350 |
Why?
| | Corticosterone | 1 | 2012 | 236 | 0.350 |
Why?
| | Wakefulness | 2 | 2024 | 125 | 0.340 |
Why?
| | eIF-2 Kinase | 2 | 2024 | 31 | 0.330 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2012 | 430 | 0.320 |
Why?
| | Raptors | 1 | 2008 | 3 | 0.310 |
Why?
| | Tacrolimus Binding Protein 1A | 1 | 2008 | 10 | 0.310 |
Why?
| | Motor Activity | 3 | 2022 | 718 | 0.300 |
Why?
| | Feces | 1 | 2012 | 484 | 0.300 |
Why?
| | Maze Learning | 5 | 2014 | 103 | 0.280 |
Why?
| | Phosphorylation | 9 | 2016 | 1759 | 0.280 |
Why?
| | Circadian Rhythm | 1 | 2012 | 468 | 0.280 |
Why?
| | Fragile X Mental Retardation Protein | 4 | 2012 | 50 | 0.280 |
Why?
| | Protein Isoforms | 2 | 2020 | 404 | 0.280 |
Why?
| | Receptors, Metabotropic Glutamate | 4 | 2014 | 40 | 0.280 |
Why?
| | Protein Kinases | 2 | 2008 | 319 | 0.270 |
Why?
| | Memory Disorders | 3 | 2015 | 164 | 0.270 |
Why?
| | Fear | 3 | 2008 | 338 | 0.260 |
Why?
| | Nervous System Diseases | 1 | 2009 | 266 | 0.260 |
Why?
| | Male | 20 | 2025 | 67762 | 0.260 |
Why?
| | RNA, Messenger | 4 | 2017 | 2833 | 0.250 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2023 | 2189 | 0.250 |
Why?
| | Analysis of Variance | 4 | 2017 | 1316 | 0.250 |
Why?
| | Protein Aggregation, Pathological | 1 | 2025 | 21 | 0.240 |
Why?
| | Phenotype | 5 | 2023 | 3196 | 0.230 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2025 | 100 | 0.230 |
Why?
| | Hydrazones | 2 | 2017 | 25 | 0.230 |
Why?
| | Anti-Anxiety Agents | 2 | 2023 | 46 | 0.230 |
Why?
| | Thiazoles | 2 | 2017 | 123 | 0.220 |
Why?
| | In Vitro Techniques | 7 | 2014 | 1092 | 0.220 |
Why?
| | Drosophila melanogaster | 2 | 2003 | 233 | 0.220 |
Why?
| | Cyclic GMP-Dependent Protein Kinase Type II | 2 | 2014 | 2 | 0.210 |
Why?
| | Coculture Techniques | 1 | 2024 | 239 | 0.210 |
Why?
| | Mutation | 3 | 2016 | 3958 | 0.210 |
Why?
| | Diazepam | 1 | 2023 | 35 | 0.210 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 3 | 2013 | 145 | 0.210 |
Why?
| | Gliosis | 1 | 2023 | 28 | 0.200 |
Why?
| | RNA, Double-Stranded | 1 | 2023 | 57 | 0.200 |
Why?
| | Cells, Cultured | 4 | 2025 | 4193 | 0.200 |
Why?
| | Vesicular Transport Proteins | 1 | 2003 | 84 | 0.200 |
Why?
| | Rats, Sprague-Dawley | 4 | 2021 | 2486 | 0.190 |
Why?
| | Suprachiasmatic Nucleus | 1 | 2022 | 16 | 0.190 |
Why?
| | Long-Term Synaptic Depression | 3 | 2014 | 56 | 0.190 |
Why?
| | Sleep Deprivation | 1 | 2024 | 174 | 0.190 |
Why?
| | Prefrontal Cortex | 2 | 2017 | 301 | 0.190 |
Why?
| | Neural Inhibition | 2 | 2017 | 169 | 0.180 |
Why?
| | Multifactorial Inheritance | 1 | 2023 | 174 | 0.180 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2024 | 248 | 0.180 |
Why?
| | Cerebral Cortex | 2 | 2016 | 433 | 0.180 |
Why?
| | Nerve Tissue Proteins | 3 | 2024 | 596 | 0.180 |
Why?
| | Spatial Behavior | 1 | 2020 | 26 | 0.170 |
Why?
| | Motor Neurons | 1 | 2023 | 234 | 0.170 |
Why?
| | Gene Regulatory Networks | 1 | 2023 | 305 | 0.170 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 135 | 0.170 |
Why?
| | Spinal Cord | 1 | 2023 | 370 | 0.170 |
Why?
| | Calcineurin | 2 | 2013 | 108 | 0.170 |
Why?
| | Cell Nucleus | 1 | 2003 | 620 | 0.160 |
Why?
| | Anxiety Disorders | 1 | 2023 | 377 | 0.160 |
Why?
| | Behavior, Addictive | 1 | 2020 | 81 | 0.160 |
Why?
| | Synaptic Transmission | 2 | 2014 | 289 | 0.160 |
Why?
| | Rats | 4 | 2021 | 5647 | 0.160 |
Why?
| | Genetic Markers | 1 | 2020 | 344 | 0.160 |
Why?
| | Artificial Intelligence | 1 | 2022 | 279 | 0.150 |
Why?
| | Amygdala | 2 | 2011 | 191 | 0.150 |
Why?
| | Memory, Short-Term | 2 | 2014 | 250 | 0.150 |
Why?
| | Electrocorticography | 1 | 2018 | 17 | 0.140 |
Why?
| | Conditioning, Classical | 2 | 2017 | 103 | 0.140 |
Why?
| | Brain Waves | 1 | 2018 | 33 | 0.140 |
Why?
| | Models, Biological | 3 | 2009 | 1783 | 0.130 |
Why?
| | Polyribosomes | 1 | 2017 | 24 | 0.130 |
Why?
| | Models, Animal | 2 | 2017 | 384 | 0.130 |
Why?
| | Neurofibrillary Tangles | 1 | 2016 | 13 | 0.130 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2017 | 156 | 0.130 |
Why?
| | Association Learning | 1 | 2017 | 61 | 0.130 |
Why?
| | Cell Differentiation | 1 | 2024 | 1991 | 0.130 |
Why?
| | Pyramidal Cells | 1 | 2017 | 74 | 0.130 |
Why?
| | CA1 Region, Hippocampal | 2 | 2014 | 52 | 0.130 |
Why?
| | Transcription Factors | 2 | 2022 | 1719 | 0.120 |
Why?
| | Dynamins | 1 | 2015 | 37 | 0.120 |
Why?
| | Sex Characteristics | 1 | 2020 | 762 | 0.120 |
Why?
| | Female | 9 | 2023 | 73304 | 0.120 |
Why?
| | Haloperidol | 2 | 2014 | 34 | 0.120 |
Why?
| | Antipsychotic Agents | 2 | 2014 | 194 | 0.120 |
Why?
| | Humans | 18 | 2025 | 137585 | 0.110 |
Why?
| | Maternal-Fetal Exchange | 1 | 2016 | 165 | 0.110 |
Why?
| | Th17 Cells | 1 | 2016 | 108 | 0.110 |
Why?
| | Alcoholism | 1 | 2021 | 807 | 0.110 |
Why?
| | Neuroimaging | 1 | 2017 | 259 | 0.110 |
Why?
| | Pyridines | 3 | 2013 | 506 | 0.110 |
Why?
| | Electric Stimulation | 3 | 2014 | 264 | 0.110 |
Why?
| | Antibodies | 1 | 2016 | 410 | 0.110 |
Why?
| | Social Behavior | 1 | 2017 | 287 | 0.110 |
Why?
| | Cell Count | 2 | 2013 | 324 | 0.110 |
Why?
| | GABA-A Receptor Agonists | 1 | 2013 | 16 | 0.100 |
Why?
| | Excitatory Postsynaptic Potentials | 2 | 2011 | 124 | 0.100 |
Why?
| | Sterols | 1 | 2012 | 18 | 0.100 |
Why?
| | Nitro Compounds | 1 | 2012 | 6 | 0.100 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2013 | 131 | 0.100 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2014 | 198 | 0.100 |
Why?
| | Multiprotein Complexes | 1 | 2014 | 163 | 0.100 |
Why?
| | Smoking | 1 | 2020 | 1627 | 0.100 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2017 | 752 | 0.100 |
Why?
| | Photoperiod | 1 | 2012 | 52 | 0.090 |
Why?
| | Gene Deletion | 1 | 2013 | 391 | 0.090 |
Why?
| | Reaction Time | 1 | 2013 | 412 | 0.090 |
Why?
| | Ribosomal Protein S6 | 1 | 2011 | 15 | 0.090 |
Why?
| | Motor Skills | 1 | 2012 | 97 | 0.090 |
Why?
| | Dopamine and cAMP-Regulated Phosphoprotein 32 | 1 | 2011 | 9 | 0.090 |
Why?
| | Amyloid beta-Peptides | 2 | 2011 | 220 | 0.090 |
Why?
| | Sirolimus | 2 | 2011 | 276 | 0.090 |
Why?
| | Primary Cell Culture | 1 | 2012 | 171 | 0.090 |
Why?
| | Dopamine | 1 | 2014 | 303 | 0.090 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 2 | 2008 | 35 | 0.090 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 2 | 2014 | 188 | 0.090 |
Why?
| | Oxidants | 1 | 2011 | 111 | 0.090 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2011 | 136 | 0.080 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 1774 | 0.080 |
Why?
| | Genotype | 2 | 2014 | 1916 | 0.080 |
Why?
| | Superoxides | 1 | 2011 | 202 | 0.080 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2016 | 605 | 0.080 |
Why?
| | Enzyme Inhibitors | 2 | 2011 | 840 | 0.080 |
Why?
| | Oxidative Stress | 1 | 2015 | 1317 | 0.080 |
Why?
| | Exploratory Behavior | 1 | 2008 | 92 | 0.070 |
Why?
| | Peptide Elongation Factor 1 | 1 | 2008 | 9 | 0.070 |
Why?
| | Ribosomal Protein S6 Kinases | 1 | 2008 | 21 | 0.070 |
Why?
| | Membrane Proteins | 1 | 2014 | 1164 | 0.070 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2007 | 141 | 0.070 |
Why?
| | Activating Transcription Factor 4 | 1 | 2007 | 20 | 0.070 |
Why?
| | In Situ Hybridization | 1 | 2007 | 316 | 0.070 |
Why?
| | Space Perception | 1 | 2008 | 80 | 0.070 |
Why?
| | Pregnancy | 2 | 2017 | 6763 | 0.070 |
Why?
| | Eukaryotic Initiation Factor-2 | 1 | 2007 | 29 | 0.070 |
Why?
| | Eukaryotic Initiation Factors | 2 | 2021 | 10 | 0.070 |
Why?
| | Granulomatous Disease, Chronic | 1 | 2006 | 55 | 0.060 |
Why?
| | Neuromuscular Junction | 2 | 2003 | 57 | 0.060 |
Why?
| | Sex Factors | 1 | 2012 | 2071 | 0.060 |
Why?
| | Infant, Newborn | 1 | 2017 | 6079 | 0.060 |
Why?
| | Larva | 2 | 2003 | 226 | 0.060 |
Why?
| | Cohort Studies | 1 | 2015 | 5742 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinases | 2 | 2003 | 313 | 0.060 |
Why?
| | Protein Binding | 1 | 2011 | 2224 | 0.060 |
Why?
| | Sleep, REM | 1 | 2024 | 33 | 0.060 |
Why?
| | Drosophila | 1 | 2025 | 154 | 0.050 |
Why?
| | Time Factors | 2 | 2012 | 6828 | 0.050 |
Why?
| | Electrodes | 1 | 2024 | 114 | 0.050 |
Why?
| | N-Ethylmaleimide-Sensitive Proteins | 1 | 2003 | 5 | 0.050 |
Why?
| | Carrier Proteins | 2 | 2010 | 771 | 0.050 |
Why?
| | Learning | 1 | 2008 | 409 | 0.050 |
Why?
| | Calcium-Transporting ATPases | 1 | 2003 | 40 | 0.050 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2003 | 38 | 0.050 |
Why?
| | CCAAT-Enhancer-Binding Proteins | 1 | 2003 | 37 | 0.050 |
Why?
| | Body Temperature | 1 | 2024 | 222 | 0.050 |
Why?
| | Cell Adhesion Molecules, Neuronal | 1 | 2003 | 41 | 0.050 |
Why?
| | Blood-Brain Barrier | 1 | 2024 | 138 | 0.050 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2003 | 124 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2003 | 134 | 0.050 |
Why?
| | Mice, Inbred Strains | 1 | 2023 | 409 | 0.050 |
Why?
| | Paralysis | 1 | 2003 | 71 | 0.050 |
Why?
| | Methoxyhydroxyphenylglycol | 2 | 2014 | 13 | 0.050 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2024 | 243 | 0.050 |
Why?
| | Species Specificity | 1 | 2023 | 585 | 0.050 |
Why?
| | Transcription Factor AP-1 | 1 | 2002 | 92 | 0.050 |
Why?
| | Adult | 2 | 2017 | 37929 | 0.050 |
Why?
| | Electroencephalography | 1 | 2024 | 423 | 0.050 |
Why?
| | Drosophila Proteins | 1 | 2003 | 204 | 0.040 |
Why?
| | Central Nervous System | 1 | 2003 | 258 | 0.040 |
Why?
| | Psychopathology | 1 | 2021 | 56 | 0.040 |
Why?
| | Lipopolysaccharides | 1 | 2024 | 886 | 0.040 |
Why?
| | Receptors, AMPA | 2 | 2012 | 141 | 0.040 |
Why?
| | Bombyx | 1 | 2000 | 6 | 0.040 |
Why?
| | Temperature | 1 | 2003 | 679 | 0.040 |
Why?
| | Apolipoproteins | 1 | 2000 | 33 | 0.040 |
Why?
| | Seizures | 1 | 2003 | 426 | 0.040 |
Why?
| | Ultrasonography | 1 | 2003 | 759 | 0.040 |
Why?
| | NADPH Oxidase 2 | 2 | 2011 | 39 | 0.040 |
Why?
| | NADPH Oxidases | 2 | 2011 | 113 | 0.040 |
Why?
| | Age of Onset | 1 | 2020 | 518 | 0.040 |
Why?
| | Prepulse Inhibition | 1 | 2017 | 8 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2002 | 860 | 0.030 |
Why?
| | Child, Preschool | 1 | 2012 | 11074 | 0.030 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2017 | 45 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 2 | 2010 | 366 | 0.030 |
Why?
| | Reflex, Startle | 1 | 2017 | 65 | 0.030 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 1 | 2017 | 97 | 0.030 |
Why?
| | Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2016 | 14 | 0.030 |
Why?
| | Membrane Glycoproteins | 2 | 2011 | 500 | 0.030 |
Why?
| | Antibodies, Blocking | 1 | 2016 | 33 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2017 | 390 | 0.030 |
Why?
| | Receptors, Retinoic Acid | 1 | 2016 | 43 | 0.030 |
Why?
| | Behavioral Symptoms | 1 | 2016 | 42 | 0.030 |
Why?
| | CRISPR-Cas Systems | 1 | 2017 | 125 | 0.030 |
Why?
| | Young Adult | 1 | 2012 | 13209 | 0.030 |
Why?
| | Alcohol Drinking | 1 | 2021 | 828 | 0.030 |
Why?
| | Electrical Synapses | 1 | 2014 | 11 | 0.030 |
Why?
| | Tobacco Use Disorder | 1 | 2017 | 251 | 0.030 |
Why?
| | Biophysical Phenomena | 1 | 2014 | 64 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2014 | 125 | 0.030 |
Why?
| | Rotarod Performance Test | 1 | 2012 | 16 | 0.030 |
Why?
| | Post-Synaptic Density | 1 | 2012 | 11 | 0.020 |
Why?
| | Microtubule-Associated Proteins | 1 | 2014 | 196 | 0.020 |
Why?
| | Cyclic GMP | 1 | 2012 | 93 | 0.020 |
Why?
| | Schizophrenia | 1 | 2017 | 439 | 0.020 |
Why?
| | Adolescent | 1 | 2012 | 21513 | 0.020 |
Why?
| | Aged | 1 | 2012 | 23961 | 0.020 |
Why?
| | Child | 1 | 2012 | 21935 | 0.020 |
Why?
| | Gene Knock-In Techniques | 1 | 2011 | 56 | 0.020 |
Why?
| | Emetine | 1 | 2011 | 7 | 0.020 |
Why?
| | Bicuculline | 1 | 2011 | 23 | 0.020 |
Why?
| | Onium Compounds | 1 | 2011 | 9 | 0.020 |
Why?
| | rap GTP-Binding Proteins | 1 | 2011 | 6 | 0.020 |
Why?
| | GABA-A Receptor Antagonists | 1 | 2011 | 19 | 0.020 |
Why?
| | Ubiquinone | 1 | 2011 | 29 | 0.020 |
Why?
| | Electrophysiological Phenomena | 1 | 2011 | 58 | 0.020 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2011 | 100 | 0.020 |
Why?
| | Biphenyl Compounds | 1 | 2011 | 63 | 0.020 |
Why?
| | Isoproterenol | 1 | 2011 | 113 | 0.020 |
Why?
| | Flavonoids | 1 | 2011 | 85 | 0.020 |
Why?
| | Biophysics | 1 | 2011 | 71 | 0.020 |
Why?
| | Organophosphorus Compounds | 1 | 2011 | 78 | 0.020 |
Why?
| | Adrenergic beta-Agonists | 1 | 2011 | 134 | 0.020 |
Why?
| | Eukaryotic Initiation Factor-4A | 1 | 2010 | 5 | 0.020 |
Why?
| | Patch-Clamp Techniques | 1 | 2011 | 286 | 0.020 |
Why?
| | Oncogene Protein v-akt | 1 | 2010 | 24 | 0.020 |
Why?
| | Middle Aged | 1 | 2012 | 33479 | 0.020 |
Why?
| | Colorado | 1 | 2020 | 4565 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2010 | 155 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2011 | 810 | 0.020 |
Why?
| | Serine | 1 | 2010 | 141 | 0.020 |
Why?
| | Superoxide Dismutase | 1 | 2011 | 346 | 0.020 |
Why?
| | RNA 5' Terminal Oligopyrimidine Sequence | 1 | 2008 | 1 | 0.020 |
Why?
| | Reactive Oxygen Species | 1 | 2011 | 622 | 0.020 |
Why?
| | Autistic Disorder | 1 | 2010 | 204 | 0.020 |
Why?
| | Phosphoproteins | 1 | 2010 | 338 | 0.020 |
Why?
| | Antioxidants | 1 | 2011 | 584 | 0.020 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 171 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 2057 | 0.020 |
Why?
| | Peptide Fragments | 1 | 2010 | 706 | 0.020 |
Why?
| | Conditioning, Operant | 1 | 2006 | 100 | 0.020 |
Why?
| | Immunosuppressive Agents | 1 | 2011 | 890 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2010 | 617 | 0.020 |
Why?
| | Cognition Disorders | 1 | 2010 | 496 | 0.020 |
Why?
| | Taste | 1 | 2008 | 229 | 0.010 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2006 | 219 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2002 | 55 | 0.010 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2002 | 162 | 0.010 |
Why?
| | Electrophysiology | 1 | 2002 | 217 | 0.010 |
Why?
| | Dimerization | 1 | 2002 | 199 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2002 | 185 | 0.010 |
Why?
| | Cyclic AMP | 1 | 2002 | 234 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2000 | 272 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2002 | 1250 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2000 | 2139 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2000 | 2900 | 0.010 |
Why?
|
|
Hoeffer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|